STOCK TITAN
  1. Home
  2. News
  3. PHAT

Phathom Pharmaceuticals Inc - PHAT STOCK NEWS

Welcome to our dedicated news page for Phathom Pharmaceuticals (Ticker: PHAT), a resource for investors and traders seeking the latest updates and insights on Phathom Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Phathom Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Phathom Pharmaceuticals's position in the market.

News
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
Rhea-AI Summary
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) reported FDA approval of VOQUEZNA® tablets for Erosive GERD and heartburn relief in adults, marking the first major innovation in the U.S. Erosive GERD market in over 30 years. Commercial availability expected December 2023. NDA submitted for Non-Erosive GERD. Financially, third quarter 2023 net loss was $43.2 million, with $213.7 million in cash and cash equivalents as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
earnings
-
News
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
Rhea-AI Summary
Phathom Pharmaceuticals announced that the U.S. FDA has approved VOQUEZNA® (vonoprazan) tablets for the treatment of Erosive Esophagitis and Erosive GERD. The drug met primary and secondary endpoints in a Phase 3 trial and is expected to be commercially available in December 2023. Phathom will receive $175 million under its revenue interest financing agreement. A conference call and webcast are scheduled for November 2, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.96%
Tags
fda approval
-
News
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
Rhea-AI Summary
Phathom Pharmaceuticals has received FDA approval for the reformulation of vonoprazan tablets for the treatment of Helicobacter pylori (H. pylori) infection in adults. The reformulated tablets will be available in two treatment options, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which contain antibiotics packaged with vonoprazan, a novel potassium-competitive acid blocker. This is the first innovative acid suppressant from a new drug class approved in the U.S. in over 30 years. The company plans to launch these treatments in December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
fda approval
News
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Phathom Pharmaceuticals to participate in investor conferences in November
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
conferences
-
News
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
Rhea-AI Summary
Phathom Pharmaceuticals submits NDA for vonoprazan as a daily treatment for Non-Erosive GERD, supported by positive Phase 3 results. FDA action expected in Q3 2024. Potential advancement for 38M U.S. adults suffering from GERD. Vonoprazan demonstrated durable heartburn control over 6 months. Adverse events comparable to placebo. 10-month regulatory review expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags
none
-
News
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Phathom Pharmaceuticals to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.27%
Tags
conferences
News
Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
Rhea-AI Summary
Phathom Pharmaceuticals submits six-month stability data for vonoprazan tablets to FDA for Erosive GERD treatment. Data shows effective control of N-nitroso-vonoprazan (NVP) with levels 10x below acceptable limit. Planned launch in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
none
-
News
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.73%
Tags
earnings
-
News
Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
Rhea-AI Summary
Phathom Pharmaceuticals closes sale of additional shares of common stock, raising approximately $150.3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
News
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
conferences
Stock PHAT logo
Phathom Pharmaceuticals Inc

Nasdaq:PHAT

PHAT Rankings

#2907 Ranked by Market Cap
#3223 Ranked by Stock Gains
N/A Ranked by Dividends

PHAT Stock Data

592.96M
42.90M
8.81%
87.86%
18.21%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Florham Park

About PHAT

phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.